Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Jacob D Soumerai,Catherine S Diefenbach,Felipe Samaniego,Abhijeet Kumar,Michaela L Tsai,Adam S Asch,Deepa Jagadeesh,Vaishalee P Kenkre,Izidore S Lossos,Huda Salman,Farrukh T Awan,Lu Miao,Richard G Ghalie,Andrew D Zelenetz

doi:10.1182/blood-2022-157563

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Jacob D Soumerai, Catherine S Diefenbach + Show 12 more

Open Access

https://doi.org/10.1182/blood-2022-157563

Copy DOI

Journal: Blood	Publication Date: Nov 15, 2022
Citations: 2

Affiliation: Massachusetts General Hospital, New York University, The University of Texas MD Anderson Cancer Center, University of Arizona, University of Oklahoma Health Sciences Center, Cleveland Clinic, University of Wisconsin–Madison, Sylvester Comprehensive Cancer Center, Stony Brook University, The University of Texas Southwestern Medical Center, MEI Pharma (United States), Kettering University, Memorial Sloan Kettering Cancer Center

#Follicular Lymphoma #Mantle Cell Lymphoma + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.